Trials / Completed
CompletedNCT02098278
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Catabasis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride clearance. This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
Conditions
- Lipoprotein Lipase Deficiency, Familial
- Hyperlipoproteinemia Type I
- Chylomicronemia, Familial
- Hypertriglyceridemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAT-2003 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-03-28
- Last updated
- 2016-07-21
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02098278. Inclusion in this directory is not an endorsement.